Paranova is a Danish pharmaceutical company founded in 1989, focused on ensuring high quality and lower prices on original high-quality pharmaceuticals. The company operates by purchasing original pharmaceuticals from licensed wholesalers in EU countries with lower prices and importing them into Denmark, Sweden, and Finland. This process allows them to create competitive pricing and save money for patients and taxpayers. Paranova is part of the MPA Pharma group, the 3rd biggest reimport group in Europe, based in Germany. The MPA Pharma group's revenue surpassed 1 billion Danish kroner in both 2016 and 2017, with over 17 million repackaged pharmaceuticals, and further growth is anticipated.Paranova's philosophy revolves around providing high-quality pharmaceuticals and transparency throughout the process. They emphasize building and sustaining strong partnerships, continuous improvement, and adaptability to change, which they believe drives better business and performance.
While Paranova has a strong standing in the Nordic pharmaceutical industry, it currently does not have any disclosed investments or investors.
Business keywords:
Pharmaceuticals, Distribution, Import/Export, Partnerships, Quality Control, Reimport, European Union, Purchasing, Nordic Industry, Marketing Authorization, Cost Efficiency, International Business